烟囱腔内主动脉修复术中期结局:系统综述与荟萃分析
汇总3年总生存率81.4%(95%CI 73.8-87.9),免于再干预率85.7%(95%CI 75.6-93.5),靶血管通畅率95.1%(95%CI 89.3-98.7)。结论认为ChEVAR中期耐久性良好,可作为高危JAAA患者的合适替代方案。
要点
- ChEVAR治疗近肾腹主动脉瘤3年总生存率81.4%,免于再干预率85.7%。
- 3年靶血管通畅率达95.1%,中期耐久性良好。
- 纳入研究方法学质量为中等至差,需更多大样本前瞻性研究验证长期结局。
核心结论
- ChEVAR治疗近肾腹主动脉瘤可获得良好至可接受的短期和中期生存率及良好的中期耐久性。
- ChEVAR可作为高危近肾腹主动脉瘤患者的合适替代方案,但需严格选择患者。
- 需进一步大规模前瞻性高质量研究以证实长期结果并明确结局决定因素。
研究设计与样本
- 系统综述与荟萃分析,检索多个电子数据库至2020年1月。
- 纳入标准:描述ChEVAR治疗近肾腹主动脉瘤中或长期结局(平均随访至少1年)、病例数>10例、英文全文发表的研究。
- 使用MINORS标准评估纳入研究质量,采用随机效应模型汇总效应量,I2统计量检验异质性。
主要发现
- 汇总3年总生存率为81.4%(95%CI 73.8-87.9)。
- 汇总3年免于再干预率为85.7%(95%CI 75.6-93.5)。
- 汇总3年靶血管通畅率为95.1%(95%CI 89.3-98.7)。
- 方法学质量评估为中等至差。
临床怎么用
- ChEVAR可作为高危近肾腹主动脉瘤患者的替代治疗选择。
- 应注重合适的患者选择以获得良好的中期结局。
局限性
- 纳入研究方法学质量为中等至差。
- 缺乏大规模前瞻性高质量研究,长期结果尚不明确。
- 无法得出特定结局决定因素的结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To provide an overview of the literature on the mid-term outcomes of chimney EVAR (ChEVAR) for the treatment of juxtarenal abdominal aortic aneurysms (JAAA). METHODS: Different electronic databases were searched for published articles up to January 2020. The eligibility criteria were studies describing mid- or long-term outcomes of chimney EVAR (mean follow-up at least 1 year) for treatment of JAAA, including more than 10 cases, published in English, and with full text available. The outcomes measure were overall survival rate, target vessel patency, and freedom from reintervention at 3 years. Quality of the included studies was analyzed using the MINORS criteria. Pooled effect estimates were analyzed using random-effect models and heterogeneity was tested using I2 statistics. RESULTS: Thirteen articles met the inclusion criteria. The included studies described 1,019 patients. According to the quality assessment, methodological quality was moderate to poor. The pooled overall survival, freedom from reintervention, and target vessel patency at 3 year was 81.4 % (95%CI 73.8-87.9), 85.7% (95%CI 75.6-93.5), and 95.1% (95%CI 89.3-98.7) respectively. CONCLUSIONS: The results of this review show good to acceptable short and mid-term survival and good mid-term durability, which supports that ChEVAR as a suitable alternative in high-risk JAAA. However, proper patient selection for ChEVAR seems essential to attain good mid-term outcomes, and further large prospective and good quality studies are required to demonstrate its long-term results and enable conclusions on specific determinants for outcome.
引用
- Prapassaro T, Teraa M, Chinsakchai K, et al. Mid-Term Outcomes of Chimney Endovascular Aortic Aneurysm Repair: A Systematic Review and Meta-analysis. Ann Vasc Surg. 2021. PMID: 34666145. doi:10.1016/j.avsg.2021.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。